Merck KGaA, identified by its stock ticker MKGAY, has acknowledged it is in advanced negotiations with SpringWorks Therapeutics (SWTX, Financial) regarding a potential acquisition. The proposed transaction centers around a purchase price of approximately $47 per share.
While these discussions have reached a late stage, Merck emphasized that no definitive decision has been reached, and no binding agreement has been formalized at this time. This development highlights Merck's strategic interest in expanding its pharmaceutical capabilities through acquisitions.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for SpringWorks Therapeutics Inc (SWTX, Financial) is $72.50 with a high estimate of $84.00 and a low estimate of $63.00. The average target implies an upside of 61.19% from the current price of $44.98. More detailed estimate data can be found on the SpringWorks Therapeutics Inc (SWTX) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, SpringWorks Therapeutics Inc's (SWTX, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
